Loading stock…

Insmed Incorporated (INSM) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Insmed Incorporated

INSMMarket cap $23BPrice $105.2

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops drugs for rare and serious diseases, including the first FDA-approved treatment for a stubborn lung infection that had zero options for decades. Its pipeline now stretches into rare respiratory and inflammatory conditions most biotechs won't touch.

In Bastion Portfolios?

52W Return-37%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+35%10

Revenue Forecast

Rev CAGR (1y)+198%10

Rev CAGR (3y)+86%10

Rev CAGR (5y)+59%10

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+20%5

EPS Growth Y+3+410%10

Quality

Margins

EBIT Margin-71%1

Net Income Margin-77%1

Free Cash Flow Margin-71%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-87%1

ROA-38%1

Earnings Stabilityna–

GEAR+VERY WEAK15

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)351

P/BV30.31

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield-3.5%2

Dividend Yieldna–

Momentum

Short term

1 month return-17%1

3 month return-7%4

YTD return-40%1

Mid term

Price vs 52wHigh49%1

1 year return-35%1

Long term

3 year return+331%10

5 year return+281%9

Risk Shield

Price Risk

Beta0.95

Volatility62%2

Free Cash Flow

Free Cash Flow Margin-71%1

Free Cash Flow Yield-3.5%2

Quality

ROCE-42%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

INSMInsmed

Revenue FY25$364M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+35%10

Revenue, next 1Y+198%10

Revenue, next 3Y, CAGR+86%10

Revenue, next 5Y, CAGR+59%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+410%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 35%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 86%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 35%/yr over the last 3 years and is set to grow 86%/yr from here.

The runway holds up: revenue is set to grow 59%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-17%1

3-month return-7%4

YTD return-40%1

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-35%1

3-year return+331%10

5-year return+281%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +331% over three years and +281% over five, ahead of 90% of the market.

WATCH

Returns sit at the market level over three months (-7%).

WEAKNESSES

It's down 35% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-17%) and so far this year (-40%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Insmed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

INSMInsmed

Revenue FY25$364M

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+35%10

Revenue, next 1Y+198%10

Revenue, next 3Y, CAGR+86%10

Revenue, next 5Y, CAGR+59%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26ELoss1

EPS growth, FY27E0%5

EPS growth, FY28E+410%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 35%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 86%/yr over the next 3 years, ahead of most of the market.10/10

Revenue grew 35%/yr over the last 3 years and is set to grow 86%/yr from here.

The runway holds up: revenue is set to grow 59%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's speeding up. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK27 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-17%1

3-month return-7%4

YTD return-40%1

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-35%1

3-year return+331%10

5-year return+281%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +331% over three years and +281% over five, ahead of 90% of the market.

WATCH

Returns sit at the market level over three months (-7%).

WEAKNESSES

It's down 35% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-17%) and so far this year (-40%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Insmed. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community